Stock Analysts

Petrobras (PBR) Loses Wage Lawsuit, to Pay $4.5 Billion

Petróleo Brasileiro S.A. or Petrobras PBR recently lost a wage lawsuit when Brazil’s Labor Court voted in favor of the workers of Petrobras seeking higher wages. This is notably the biggest lawsuit that the company has faced in the Brazil’s Labor Court, which is expected to cost the company around 17 billion reals or 4.5 billion in U.S […]

Stock Analysts

Toll Brothers (TOL) Gains from Solid Demand, Rising Costs Hurt

Strong housing demand and lack of competition in the luxury new home market are favoring Toll Brothers Inc TOL . Overall fundamentals of the housing market were strong in 2017 and are expected to improve further in the rest of 2018. Steady job and wage growth, recovering economy, moderate home price gains, rising rentals, rapidly increasing household formation and a limited supply of inventory indicate consistent strong demand through 2018. […]

Mergers & Acquisitions

Atlas Travel Announces Flagship Acquisition

Atlas Travel Announces Flagship Acquisition PR Newswire MARLBOROUGH, Mass., June 25, 2018 MARLBOROUGH, Mass. , June 25, 2018 /PRNewswire/ — On Tuesday May 22 nd , locally-based Atlas Travel expanded its leisure expertise through the acquisition of Flagship Travel. […]

Stock Analysts

Merck (MRK) Presents New Data from Januvia Diabetes Studies

Merck & Co., Inc MRK presented new data from two studies, evaluating its type II diabetes drug Januvia (sitagliptin) as a treatment option on type II diabetes patients, who initiate insulin therapy and those with a mild renal impairment. The CompoSIT-I study showed higher reduction of blood glucose level in patients, who initiated insulin dosage while continuing treatment with Januvia compared with those who discontinued Januvia. The CompoSIT-R trial evaluated subjects with mild renal impairment, who were not adequately controlled by metformin. […]

Stock Analysts

Roche’s (RHHBY) Study on Tecentriq for Lung Cancer Positive

Roche Holdings RHHBY announced that the phase III study, IMpower133, on immuno-oncology drug, Tecentriq, met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) at its first interim analysis for the indication of extensive-stage small cell lung cancer (ES-SCLC). The study enrolled 403 people who were randomised equally (1: 1 ) to receive either Tecentriq in combination with carboplatin and etoposide (Arm A), or placebo in combination with carboplatin and etoposide (Arm B, control arm). The results of the study showed that initial (first-line) treatment with the combination of Tecentriq and chemotherapy (carboplatin and etoposide) enabled patients with ES-SCLC live significantly longer compared to chemotherapy alone. […]

Stock Analysts

Why is FedEx (FDX) Stock Down 6% Despite Strong Q4 Earnings?

Shares of FedEx Corporation FDX declined 6.2% to $241.77 post the earnings release on Jun 19, despite reporting better-than-expected revenues and earnings per share in the fourth quarter of fiscal 2018. Reasons Behind the Stock’s Plunge The escalating fears of a trade war hampering the free flow of goods between countries are the main reasons behind the stock’s dismal performance. […]